Q-omics provides the consensus-scored KIF4B profile across patient tissues and cancer cell-line models. KIF4B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KIF4B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, KIF4B RNA expression shows 14,721 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where KIF4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF4B survival associations across molecular data types. KIF4B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF4B RNA expression–survival associations across cancer types. High KIF4B expression shows unfavorable associations in KIRP, ACC, MESO, LIHC and HNSC, but favorable associations in SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KIF4B RNA expression.
This table summarizes KIF4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF4B shows higher tumor expression in KIRC, KIRP, HNSC, COAD, STAD and BLCA. The KIRC box plot shows higher KIF4B RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p < 0.001).
This table shows molecular features associated with KIF4B in patient tissues and cancer cell lines. In patient samples, KIF4B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
